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In Response:
We would like to thank Troost 
et al. for their interest in our work 
regarding personalizing prescription 
doses using genetic data.1 The authors 
with a favorable profile while seeking 
alternative therapeutic options in the 
remaining patients.
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model a reduction in prescribed dose 
would be necessary in 26 of the 141 
patients studied. All but one of these 
patients belonged to the cohort that 
developed radiation pneumonitis. The 
mean clinically prescribed dose to this 
pneumonitis population was 64.7 Gy as 
opposed to 51.8 Gy predicted to be safe 
by the model. For a subset of the remain-
ing patients, the dose could be slightly 
increased or decreased. This finding is 
intriguing keeping in mind that dose 
escalation in lung radiotherapy is thought 
to substantially increase local tumor con-
trol and ultimately survival.4 Instead of 
decreasing the dose to prevent patients 
from developing unwanted side effects, 
more tailored solutions are feasible. van 
Baardwijk et al.5 successfully pioneered 
an individualized approach escalating 
dose to maximal tolerance while keep-
ing within the normal-tissue constraints, 
both theoretically and clinically. Both 
acute and late toxicity were acceptable. 
Additionally, MAASTRO clinic is cur-
rently conducting a randomized phase II 
trial including 18F-fluorodeoxyglucose-
positron emission tomography informa-
tion for tumor (subvolume) boosting 
(NCT01024829). On the basis of a recent 
in silico study,3 Radboud University 
Nijmegen Medical Centre is carrying 
out the Individualized Dose Escalation 
in Advanced stage non-small cell Lung 
cancer using Volumetric Modulated 
Arc Therapy (IDEAL-VMAT) study 
(NCT01577212), whereby the irradia-
tion dose is increased on an individual 
basis, taking into account multiple 
 normal-tissue constraints.
For patients with both an unfavor-
able genetic profile and dose distribu-
tion, the radiation dose that can be safely 
administered on the basis of the proposed 
model is probably not curative. Therefore, 
the treating radiation oncologist may opt 
for a palliative protocol thereby deceler-
ating tumor progression and alleviating 
tumor-associated complaints while pre-
venting patients from unnecessary treat-
ment-related side effects.
In summary, this article on 
model-based prescription provides new, 
yet prospectively unvalidated, tools 
for individualized dose-prescription in 
non–small-cell lung cancer patients. 
Radiation oncologists are encouraged 
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To the Editor:
With great interest, we read the 
recent publication by Vinogradskiy et 
al.1 The authors apply their radiation 
pneumonitis prediction model combin-
ing dose-volume and genetic compo-
nents (single-nucleotide polymorphisms 
[SNPs]) for isotoxic mean lung dose 
determination. The five SNPs were 
found to predict for radiation pneumoni-
tis and interestingly, they do not directly 
relate to lung injury, but rather to cellular 
repair and the tumor microenvironment.
The authors state that radiation 
pneumonitis is the dominant dose- 
limiting constraint in thoracic radiother-
apy. This may have been the case for the 
cohort studied for 19% of the patients, 
mostly treated with three-dimensional 
conformal radiotherapy developed radi-
ation pneumonitis of grade 3 or higher. 
With the introduction of highly confor-
mal radiotherapy delivery techniques 
and by abandoning elective nodal irra-
diation, acute grade 3 esophagitis is 
increasingly the dose-limiting toxicity 
based both on clinical experience2 and 
in silico studies.3 As opposed to radia-
tion pneumonitis, this burdensome side 
effect is not fatal but gradually develops 
during the course of (chemo)radiother-
apy, lasting for several weeks thereaf-
ter necessitating analgesic medication 
and dietary alterations in the majority 
of patients. Moreover, late esophageal 
sequelae may develop, adversely influ-
encing the patients’ quality of life.
Vinogradskiy et al.1 found that on 
the basis of the isotoxic physico-genetic 
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